You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Emerito Carlos Rodriguez-Merchan -- 2269 2022-12-12 01:20:15 |
2 format Jason Zhu Meta information modification 2269 2022-12-12 02:36:33 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Rodríguez-Merchán, E.C. Intraarticular Injections of MSC in Knee Osteoarthritis. Encyclopedia. Available online: https://encyclopedia.pub/entry/38505 (accessed on 08 December 2025).
Rodríguez-Merchán EC. Intraarticular Injections of MSC in Knee Osteoarthritis. Encyclopedia. Available at: https://encyclopedia.pub/entry/38505. Accessed December 08, 2025.
Rodríguez-Merchán, Emérito Carlos. "Intraarticular Injections of MSC in Knee Osteoarthritis" Encyclopedia, https://encyclopedia.pub/entry/38505 (accessed December 08, 2025).
Rodríguez-Merchán, E.C. (2022, December 12). Intraarticular Injections of MSC in Knee Osteoarthritis. In Encyclopedia. https://encyclopedia.pub/entry/38505
Rodríguez-Merchán, Emérito Carlos. "Intraarticular Injections of MSC in Knee Osteoarthritis." Encyclopedia. Web. 12 December, 2022.
Intraarticular Injections of MSC in Knee Osteoarthritis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/ijms232314953

More than 10% of the world’s population suffers from osteoarthritis (OA) of the knee, with a lifetime risk of 45%. Treatments for knee OA pain are as follows: weight control; oral pharmacological treatment (non-steroidal anti-inflammatory drugs, paracetamol, opioids); mechanical aids (crutches, walkers, braces, orthotics); therapeutic physical exercise; and intraarticular injections of corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP). The problem is that such treatments usually relieve joint pain for only a short period of time. With respect to intraarticular injections, corticosteroids relieve pain for several weeks, while hyaluronic acid and PRP relieve pain for several months. When the above treatments fail to control knee pain, total knee arthroplasty (TKA) is usually indicated; however, although a very effective surgical technique, it can be associated with medical and postoperative (surgery-related) complications. Therefore, it seems essential to look for safe and effective alternative treatments to TKA. There has been much research on intraarticular injections of mesenchymal stem cells (MSCs) for the management of OA of the knee joint.

MSCs knee osteoarthritis mechanisms of action

1. Introduction

Primary knee osteoarthritis (OA) is a degenerative disease that causes severe joint pain, which is not easy to control, in patients who suffer from it. The increasing average life expectancy of the world’s population and the increasing prevalence of obesity make knee OA a growing economic burden on healthcare systems worldwide [1][2]. More than 10% of the world’s population has knee OA, with a lifetime risk of knee OA being 45% [3].
Current treatments for pain associated with OA include weight control; oral pharmacological treatment (non-steroidal anti-inflammatory drugs, paracetamol, opioids); mechanical aids (crutches, walkers, braces, orthotics); therapeutic physical exercise; and intraarticular injections of corticosteroids, hyaluronic acid, and platelet-rich plasma (PRP) [4][5]. However, these treatments tend to relieve joint pain only in the short term—several weeks for corticosteroids and several months for hyaluronic acid and PRP [6][7].
Given that knee OA is a chronic disease, long-term treatment typically requires a total knee arthroplasty (TKA). Although it is an effective surgical technique, it is not free from complications. Therefore, patients with knee OA whose pain cannot be controlled with the previously mentioned conservative and non-aggressive measures continue to seek therapies that are not as aggressive as TKA, such as intraarticular injections of mesenchy-mal stem cells (MSCs) [1][8][9].

2. MSCs’ Molecular Mechanisms of Action

Results of a PubMed (MEDLINE) search of studies related to MSCs in knee OA were analyzed. The searches were from the beginning of the search engine until 31 October 2022 using the keywords “Knee osteoarthritis MSCs”. Only the studies on MSCs in knee OA that the authors considered to be of most interest were included. PubMed found 391 articles, of which 77 were selected.
MSCs play significant roles in the repair and regeneration process. These include the reduction of cell death to continually replace lost cells, the secretion of trophic factors that stabilize the extracellular matrix, and the suppression of immune cell activation to prevent inflammation [10].
In one study, exosomes were harvested from ESC-MSCs in conditioned culture media by a sequential centrifugation process. Then, ESC-MSCs or their exosomes were intraarticularly injected. An in vitro model with primary mouse chondrocytes stimulated with interleukin-1 beta (IL-1β) was used to assess the impact of the conditioned medium with or without exosomes and titrated doses of isolated exosomes for two days, before immunocytochemistry or western blot analysis. Destabilization of the medial meniscus (DMM) surgery on knees of C57BL/6 J mice was used as an OA model [11]. The results revealed that exosomes from human embryonic stem cell-induced MSCs (ESC-MSCs) had a beneficial therapeutic impact against OA by balancing the production and decomposition of the extracellular matrix (ECM) of chondrocytes [11].
Using a Sprague–Dawley rat design of collagenase II and IL-1β-induced OA chondrocytes, long non-coding ribonucleic acid malat-1 from human MSC (hMSC)-delivered extracellular vesicles (EVs) promoted chondrocyte proliferation, alleviated chondrocyte inflammation and cartilage degeneration, and enhanced chondrocyte repair [12].
A study by Yang et al. used tropoelastin as the injection medium and compared it with classic media, such as normal saline, hyaluronic acid, and platelet-rich plasma (PRP), in intraarticular MSC injection. The authors found that tropoelastin promoted the emigration of infrapatellar fat pad MSCs (IPFP-MSCs) and protected knee cartilage from OA damage by enhancing cell adhesion and activating the integrin beta-1/extracellular signal-regulated protein kinase 1/2/vinculin pathway. These findings provided new insights into intraarticular injections of MSCs for the treatment of OA [13].
In one study, cultured MSCs originating from three types of tissues (bone marrow, adipose tissue, and synovium) were treated with IL-1β and tumor necrosis factor-alpha or not to attain conditioned media. Each conditioned medium was used to analyze paracrine factors related to cartilage restoration by liquid chromatography-tandem mass spectrometry. MSCs from these tissues expressed 93 proteins under normal circumstances and 105 proteins under inflammatory circumstances [14]. The differentially expressed proteins might contribute to the regeneration of damaged cartilage.
In a suspended synovium culture model, MSCs were released from the synovial membrane across a medium into a non-contacting culture dish [15]. The authors found that, in knees with OA, endogenous MSCs were possibly similarly mobilized from the synovium through the synovial fluid, acting in a protective manner. In the natural course of OA, however, the number of mobilized MSCs is limited, leading to OA progression. In a rat OA model, it was also noticed that injections of synovial MSCs inhibited the progression of cartilage degeneration. The injected synovial MSCs emigrated into the synovial membrane, maintained their MSC characteristics, and augmented gene expressions of TSG-6, PRG-4, and bone morphogenetic protein-2. That is, exogenous synovial MSCs could facilitate anti-inflammation, lubrication, and formation of cartilage matrix in osteoarthritic knees [15].
It has been shown that chronic swelling results in excess Ca2+ transfer from the endoplasmic reticulum to the mitochondria, leading to mitochondrial calcium overload and further mitochondrial harm [16]. Moreover, under conditions of chronic inflammation, injured mitochondria accumulate over time in MSCs due to mitophagy by activation of the Wnt/β-catenin pathway, which impairs MSC differentiation. Zhai et al. isolated tissue-specific MSCs in the periodontal ligament, termed periodontal ligament stem cells, from healthy patients and patients with periodontitis. Based on the mechanistic invention, intracellular microenvironment (esterase and low pH)-responsive nanoparticles were constructed to capture Ca2+ surrounding mitochondria in MSCs to control MSC mitochondrial calcium flux against mitochondrial dysfunction. The nanoparticles were able to liberate siRNA from MSCs to restrain the Wnt/β-catenin pathway and control mitophagy of the initially dysfunctional mitochondria. The aforementioned nanoparticles (“nanorepairers”) physiologically reestablished the activity of mitochondria and MSCs, which could be a new effective therapy against OA [16]. 

3. Experimental Studies

A systematic review of animal studies concluded that intraarticular injections of MSCs could not be recommended for knee OA clinical trials. They also stated that, based on the internal and external validity of animal studies, high-quality experimental studies and greater efforts to translate preclinical studies to clinical trials were required at that time (in 2018) [17].
The safety and efficacy of intraarticular allogenic MSC injections was investigated in a pig OA experiment after bilateral medial knee meniscectomy [18]. Bone marrow-originated MDCs (BM-MSCs) were labelled with superparamagnetic iron oxide (SPIO) nanoparticles to permit cell tracing by magnetic resonance imaging (MRI). At a concentration of ≤20 µg/mL, SPIO nanoparticles were not toxic to BM-MSCs. Four weeks following surgery, OA lesions were noticed on the MRI. Between 8 and 24 h after the injections, the SPIO-marked BM-MSCs were displaced into the damaged portion of the cartilage. In addition, histological and immunohistochemistry analysis found no significant difference between the right knee (treatment group) and the left knee (control group). The appropriate concentration of SPIO nanoparticles for labelling BM-MSCs was 20 µg/mL, while allogenic MSCs were able to move into the impaired cartilage and accumulate around it. No significant differences were found between the treatment group and the control group [18].
One study compared the efficacy of extracorporeal shockwave therapy (ESWT), Wharton’s jelly MSCs (WJ-MSCs), and a combination of ESWT and WJ-MSCs in early knee OA in rats. The results of the pathological study, micro-computed tomography, and immunohistochemistry stain demonstrated that all three options significantly improved early knee OA. The combined therapy group augmented the bone volume and trabecular thickness, as well as diminished the synovitis more than ESWT or WJ-MSCs alone. However, there was no significant difference in the combined ESWT and WJ-MSCs, as demonstrated in the expressions of IGF-1 and transforming growth factor (TGF)-β1, and the decrease in the TUNEL activity in OA knees. Moreover, WJ-MSC therapy significantly augmented the expression of type II collagen compared with ESWT and ESWT combined with WJ-MSCs in OA knees. In the mechanistic factors analysis, a synergistic effect was observed by ESWT combined with WJ-MSCs in the expression of RUNX-2, SOX-9, and collagen Xα1 on knee OA [19].
It has been observed that IPFP-MSC-derived exosomes protected articular cartilaginous tissue from injury and improved gait anomaly in OA mice while keeping cartilage homeostasis, a mechanism that could be related to miR100-5p-regulated constraint of the mTOR-autophagy pathway. Wu et al. investigated the role and underlying mechanisms of IPFP-MSC-derived exosomes on OA in vitro and in vivo. At that time (2019), those authors stated that IPFP-MSC-derived exosomes could have utility in the treatment of knee OA, given that it was relatively easy in clinical practice to obtain human IPFP from patients with OA by arthroscopic surgery [20].
One study found that intraarticular injection of human umbilical cord MSCs expressing miR-140-5p induced cartilage self-repair in rat OA, highlighting the potential therapeutic utility of such injections in OA treatment [21]. In another study of adult male albino rats, it was observed that intraarticularly-injected umbilical cord blood MSCs cured knee OA better than when they were intravenously injected [22].
In a rat OA model, it was found that selective administration of kartogenin to synovial fluid-derived MSCs (SF-MSCs) by engineered exosomes produced a uniform dissemination of kartogenin in the cytosol, increased its effective concentration in the cell, and strongly promoted chondrogenesis of SF-MSCs in vitro and in vivo [23]. Using a rat OA model, other authors observed that exosomes from human bone marrow MSCs (BM-MSCs) had a beneficial therapeutic impact on OA by diminishing senescence and the death of chondrocytes. This result suggested that MSC-derived exosomes could have therapeutic value in OA [24].
In a rat knee OA model, it was demonstrated that low-intensity pulsed ultrasound (LIPUS) improved the therapeutic effectiveness of MSCs in cartilage reconstruction by increased autophagy-mediated exosome liberation [25]. In MSCs isolated from rat bone marrow in vitro, results showed that LIPUS facilitated exosome liberation from MSCs by triggering autophagy. The in vivo results showed that LIPUS substantially potentiated the positive impact of MSCs in OA cartilaginous tissue. This impact was substantially reduced by GW4869, an inhibitor of exosome liberation [25].
In a murine OA model, mouse ADSCs were acquired from adipose tissue and transfected with modified RNA. The results of histological and immunohistochemical analyses of knee joints harvested at 4 and 8 weeks after OA induction indicated that insulin-like growth factor 1 (IGF-1)-adipose derived stem cells (ADSCs) had a better therapeutic effect than native ADSCs. This outcome was shown by an inferior histological Osteoarthritis Research Society International score and less ECM loss. Such results supported the potential therapeutic utility of IGF-1-ADSCs for the treatment of OA and cartilage repair in clinical practice [26].
In one study, articular cartilage defects were created in the intertrochlear groove of articular cartilage in rabbit femurs. Integrin α10-MSCs were labeled with SPIO nanoparticles co-conjugated with rhodamine B to allow visualization by both MRI and fluorescence microscopy. The results showed emigration and homing of human integrin α10β1-selected MSCs to cartilage defects in the rabbit knees following intraarticular administration, as well as chondrogenic differentiation of MSCs in regenerated cartilage tissue [27].
A recent publication evaluated the effectiveness of BM-MSC management in cartilage repair, utilizing a rat experiment of monoiodoacetate-induced AO of the knee joint. OA was induced in the knee joint of rats by an intracapsular injection of monoiodoacetate (2 mg/50 μL) on day zero. The authors concluded that BM-MSCs could be an effective treatment for inflamed knees, and that their effect could be mediated by their anti-inflammatory and antioxidant potential [28].
Ai et al. found that MSCs and MSC-EVs reduced OA pain through direct action on peripheral sensory neurons [29]. In their study, the authors elicited knee OA in adult male C57BL/6J mice by DMM surgery. The DMM mice treated with MSCs and MSC-EVs did not show the pain-related behavioral changes (i.e., locomotion, digging, and sleep) that the untreated DMM mice did. The lack of pain-related behaviors in the MSC/MSC-EV-treated mice was not due to diminished joint damage, but rather to the knee-innervating sensory neuron hyperexcitability that was observed in the untreated DMM mice. Moreover, they found that NGF-induced sensory neuron hyperexcitability was averted with MSC-EV management [29].
In a medial meniscal transection pre-clinical model of OA, sodium alginate microencapsulation of human MSCs modulated the paracrine signaling response and improved the efficacy of OA treatment. Three weeks post-surgery, after OA was established, intraarticular injections of encapsulated hMSCs or nonencapsulated hMSCs were administered. Six weeks post-surgery, microstructural changes in the knee joint were quantified with micro-computed tomography. Encapsulated hMSCs diminished articular cartilage degeneration and subchondral bone remodeling [30].
In a systematic review of animal models and cell doses, it was observed that rats were the most frequently employed species for modeling knee OA, and that anterior cruciate ligament transection was the most frequent approach used for producing OA [31]. A correlation was found between the cell doses and the body weight of the animals. In clinical trials, there was a great disparity in the dose of MSCs used to manage knee OA, ranging from 1 × 106 to 200 × 106 cells, with a mean of 37.91 × 106 cells. It was also found that in preclinical and clinical studies on knee OA, MSCs have significant potential for pain relief and tissue protection [31].

References

  1. Rodriguez-Merchan, E.C. Intra-articular injections of hyaluronic acid and other drugs in the knee joint. HSS J. 2013, 9, 180–182.
  2. Li, W.; Pan, J.; Lu, Z.; Zhu, H.; Guo, J.; Xie, D. The application of platelet-rich plasma in the treatment of knee osteoarthritis: A literature review. J. Orthop. Sci. 2022, 27, 420–428.
  3. Losina, E.; Weinstein, A.M.; Reichmann, W.M.; Burbine, S.A.; Solomon, D.H.; Daigle, M.E.; Rome, B.N.; Chen, S.P.; Hunter, D.J.; Suter, E.G.; et al. Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US. Arthritis Care Res. 2013, 65, 703–711.
  4. Bannuru, R.R.; Osani, M.C.; Vaysbrot, E.E.; Arden, N.K.; Bennell, K.; Bierma-Zeinstra, S.M.A.; Kraus, V.B.; Lohmander, L.S.; Abbott, J.H.; Bhandari, M.; et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 2019, 27, 1578–1589.
  5. Bruyère, O.; Honvo, G.; Veronese, N.; Arden, N.K.; Branco, J.; Curtis, E.M.; Al-Daghri, N.M.; Herrero-Beaumont, G.; Martel-Pelletier, J.; Pelletier, J.P.; et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin. Arthritis Rheum. 2019, 49, 337–350.
  6. Machado, G.C.; Maher, C.G.; Ferreira, P.H.; Pinheiro, M.B.; Lin, C.W.; Day, R.O.; McLachlan, A.J.; Ferreira, M.L. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: Systematic review and meta-analysis of randomised placebo controlled trials. BMJ 2015, 350, h1225.
  7. Fransen, M.; McConnell, S.; Harmer, A.R.; Van der Esch, M.; Simic, M.; Bennell, K.L. Exercise for osteoarthritis of the knee. Cochrane Database Syst. Rev. 2015, 1, CD004376.
  8. Cohen, S.A.; Zhuang, T.; Xiao, M.; Michaud, J.B.; Amanatullah, D.F.; Kamal, R.N. Google trends analysis shows increasing public interest in platelet-rich plasma injections for hip and knee osteoarthritis. J. Arthroplast. 2021, 36, 3616–3622.
  9. Rodriguez-Merchan, E.C. Intra-articular platelet-rich plasma injections in knee osteoarthritis: A review of their current molecular mechanisms of action and their degree of efficacy. Int. J. Mol. Sci. 2022, 23, 1301.
  10. Doyle, E.C.; Wragg, N.M.; Wilson, S.L. Intraarticular injection of bone marrow-derived mesenchymal stem cells enhances regeneration in knee osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 2020, 28, 3827–3842.
  11. Wang, Y.; Yu, D.; Liu, Z.; Zhou, F.; Dai, J.; Wu, B.; Zhou, J.; Heng, B.C.; Zou, X.H.; Ouyang, H.; et al. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res. Ther. 2017, 8, 189.
  12. Pan, C.; Huang, W.; Chen, Q.; Xu, J.; Yao, G.; Li, B.; Wu, T.; Yin, C.; Cheng, X. LncRNA Malat-1 From MSCs-Derived extracellular vesicles suppresses inflammation and cartilage degradation in osteoarthritis. Front. Bioeng. Biotechnol. 2021, 9, 772002.
  13. Yang, J.; Wang, X.; Fan, Y.; Song, X.; Wu, J.; Fu, Z.; Li, T.; Huang, Y.; Tang, Z.; Meng, S.; et al. Tropoelastin improves adhesion and migration of intra-articular injected infrapatellar fat pad MSCs and reduces osteoarthritis progression. Bioact. Mater. 2021, 10, 443–459.
  14. Lee, Y.; Park, Y.S.; Choi, N.Y.; Kim, Y.I.; Koh, Y.G. Proteomic analysis reveals commonly secreted proteins of mesenchymal stem cells derived from bone marrow, adipose tissue, and synovial membrane to show potential for cartilage regeneration in knee osteoarthritis. Stem Cells Int. 2021, 2021, 6694299.
  15. Sekiya, I.; Katano, H.; Ozeki, N. Characteristics of MSCs in synovial fluid and mode of action of intra-articular injections of synovial MSCs in knee osteoarthritis. Int. J. Mol. Sci. 2021, 22, 2838.
  16. Zhai, Q.; Chen, X.; Fei, D.; Guo, X.; He, X.; Zhao, W.; Shi, S.; Gooding, J.J.; Jin, F.; Jin, Y.; et al. Nanorepairers rescue inflammation-induced mitochondrial dysfunction in mesenchymal stem cells. Adv. Sci. 2022, 9, e2103839.
  17. Xing, D.; Kwong, J.; Yang, Z.; Hou, Y.; Zhang, W.; Ma, B.; Lin, J. Intra-articular injection of mesenchymal stem cells in treating knee osteoarthritis: A systematic review of animal studies. Osteoarthr. Cartil. 2018, 26, 445–461.
  18. Xia, T.; Yu, F.; Zhang, K.; Wu, Z.; Shi, D.; Teng, H.; Shen, J.; Yang, X.; Jiang, Q. The effectiveness of allogeneic mesenchymal stem cells therapy for knee osteoarthritis in pigs. Ann. Transl. Med. 2018, 6, 404.
  19. Cheng, J.H.; Wang, C.J.; Chou, W.Y.; Hsu, S.L.; Chen, J.H.; Hsu, T.C. Comparison efficacy of ESWT and Wharton’s jelly mesenchymal stem cell in early osteoarthritis of rat knee. Am. J. Transl. Res. 2019, 11, 586–598.
  20. Wu, J.; Kuang, L.; Chen, C.; Yang, J.; Zeng, W.N.; Li, T.; Chen, H.; Huang, S.; Fu, Z.; Li, J.; et al. miR-100-5p-abundant exosomes derived from infrapatellar fat pad MSCs protect articular cartilage and ameliorate gait abnormalities via inhibition of mTOR in osteoarthritis. Biomaterials 2019, 206, 87–100.
  21. Geng, Y.; Chen, J.; Alahdal, M.; Chang, C.; Duan, L.; Zhu, W.; Mou, L.; Xiong, J.; Wang, M.; Wang, D. Intra-articular injection of hUC-MSCs expressing miR-140-5p induces cartilage self-repairing in the rat osteoarthritis. J. Bone Miner. Metab. 2020, 38, 277–288.
  22. Mostafa, A.; Korayem, H.E.; Fekry, E.; Hosny, S. The effect of intra-articular versus intravenous injection of mesenchymal stem sells on experimentally-induced knee joint osteoarthritis. J. Microsc. Ultrastruct. 2020, 9, 31–38.
  23. Xu, X.; Liang, Y.; Li, X.; Ouyang, K.; Wang, M.; Cao, T.; Li, W.; Liu, J.; Xiong, J.; Li, B.; et al. Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials 2021, 269, 120539.
  24. Jin, Y.; Xu, M.; Zhu, H.; Dong, C.; Ji, J.; Liu, Y.; Deng, A.; Gu, Z. Therapeutic effects of bone marrow mesenchymal stem cells-derived exosomes on osteoarthritis. J. Cell Mol. Med. 2021, 25, 9281–9294.
  25. Xia, P.; Wang, Q.; Song, J.; Wang, X.; Wang, X.; Lin, Q.; Cheng, K.; Chen, A.; Li, X. Low-intensity pulsed ultrasound enhances the efficacy of bone marrow-derived MSCs in osteoarthritis cartilage repair by regulating autophagy-mediated exosome release. Cartilage 2022, 13, 19476035221093060.
  26. Wu, H.; Peng, Z.; Xu, Y.; Sheng, Z.; Liu, Y.; Liao, Y.; Wang, Y.; Wen, Y.; Yi, J.; Xie, C.; et al. Engineered adipose-derived stem cells with IGF-1-modified mRNA ameliorates osteoarthritis development. Stem Cell Res. Ther. 2022, 13, 19.
  27. Andersen, C.; Uvebrant, K.; Mori, Y.; Aarsvold, S.; Jacobsen, S.; Berg, L.C.; Lundgren-Åkerlund, E.; Lindegaard, C. Human integrin α10β1-selected mesenchymal stem cells home to cartilage defects in the rabbit knee and assume a chondrocyte-like phenotype. Stem Cell Res. Ther. 2022, 13, 206.
  28. Hamdalla, H.M.; Ahmed, R.R.; Galaly, S.R.; Ahmed, O.M.; Naguib, I.A.; Alghamdi, B.S.; Abdul-Hamid, M. Assessment of the efficacy of bone marrow-derived mesenchymal stem cells against a monoiodoacetate-induced osteoarthritis model in Wistar rats. Stem Cells Int. 2022, 2022, 1900403.
  29. Ai, M.; Hotham, W.E.; Pattison, L.A.; Ma, Q.; Henson, F.M.D.; Smith, E.S.J. Human mesenchymal stem cells and derived extracellular vesicles reduce sensory neuron hyperexcitability and pain behaviors in murine osteoarthritis. Arthritis Rheumatol. 2022. Online ahead of print.
  30. McKinney, J.M.; Pucha, K.A.; Doan, T.N.; Wang, L.; Weinstock, L.D.; Tignor, B.T.; Fowle, K.L.; Levit, R.D.; Wood, L.B.; Willett, N.J. Sodium alginate microencapsulation of human mesenchymal stromal cells modulates paracrine signaling response and enhances efficacy for treatment of established osteoarthritis. Acta Biomater. 2022, 141, 315–332.
  31. Wang, G.; Xing, D.; Liu, W.; Zhu, Y.; Liu, H.; Yan, L.; Fan, K.; Liu, P.; Yu, B.; Li, J.J.; et al. Preclinical studies and clinical trials on mesenchymal stem cell therapy for knee osteoarthritis: A systematic review on models and cell doses. Int. J. Rheum. Dis. 2022, 25, 532–562.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Emérito Carlos Rodríguez-Merchán
View Times: 688
Revisions: 2 times (View History)
Update Date: 12 Dec 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback